Home | Welcome to Contract Pharma   
Last Updated Saturday, April 25 2015


Search Results for 'Phase II'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Contract Service Directory Companies

View All Companies »

Contract Service Directory Categories

View All Categories »

Search Results:

By Gil Roth
Published October 11, 2013
Trial showed no PML cases Read More »
By Gil Roth
Published October 9, 2013
IPT trials in patients with wet AMD and VMT Read More »
Published November 23, 2010
Abbott achieved positive results from a Phase II dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic kidney disease. Read More »
Published January 6, 2010
Gilead’s Phase II trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of GS 9350, elvitegravir and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1, met its pr Read More »
Published December 28, 2009
Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Read More »
Published December 30, 2008
King Pharmaceuticals has initiated the Phase II trial evaluating the efficacy and safety of T-62, an investigational drug for the treatment of neuropathic pain. Dr. Eric Carter, chief science officer of King, remarked, “T-62, a new chemical… Read More »
Published September 5, 2006
MAP Pharmaceuticals has initiated patient dosing in a Phase II trial evaluating MAP0004 for the treatment of acute migraine headaches. MAP0004 is an inhaled drug formulation of dihydroergotamine mesylate (DHE) administered with the company's Tempo In… Read More »
Published February 6, 2006
Isis Pharmaceuticals has initiated the development program of ISIS 301012 in patients with familial hypercholesterolemia (FH), a genetic disorder that causes extremely high cholesterol levels and results in the early onset of heart disease. ISIS 3010… Read More »
Published January 12, 2015
Gains portfolio of candidates for neuropathic pain Read More »
By Gil Roth
Published January 14, 2014
Tests CNP analog against achondoplasia in children Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On